Inder Kaul, MD, MPH

  • 2Articles
  • 2025Active
  • 14Collaborators
  • 13Citations

About

Inder Kaul, MD, MPH is affiliated with Bristol Myers Squibb, Princeton, New Jersey. Inder Kaul has authored or co-authored 2 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2025. Their work focuses on Schizophrenia/Schizoaffective Disorders.

Publications

JCP
Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia
Original Research

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

March 24, 2025

Xanomeline and trospium showed improvement in agitation as measured by the PANSS-Excited Component in participants with acute exacerbations of schizophrenia.
, , , et al
JCP
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
Original Research

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials

February 26, 2025

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe